---
title: "LSL 製藥集團向董事和員工授予了 960,000 份股票期權"
description: "LSL Pharma Group Inc. 已向其非執行董事、高管和員工授予了 960,000 份股票期權，作為其薪酬的一部分。這些期權的行使價格為每股 0.52 加元，期限為十年。非執行董事的期權立即生效，而高管和員工的期權將在三年內逐步生效，並需遵循四個月的持有期"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274717860.md"
published_at: "2026-02-03T21:50:04.000Z"
---

# LSL 製藥集團向董事和員工授予了 960,000 份股票期權

> LSL Pharma Group Inc. 已向其非執行董事、高管和員工授予了 960,000 份股票期權，作為其薪酬的一部分。這些期權的行使價格為每股 0.52 加元，期限為十年。非執行董事的期權立即生效，而高管和員工的期權將在三年內逐步生效，並需遵循四個月的持有期

LSL Pharma Group Inc. 已向其非執行董事、高管和員工授予總計 960,000 股股票期權，作為其薪酬的一部分。這些期權的行使價格為每股 0.52 加元，期限為十年。非執行董事的期權立即生效，而授予高管和員工的期權將在三年內逐步生效。所有期權均需遵循四個月的持有期。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。LSL Pharma Group Inc. 於 2026 年 2 月 3 日通過 CNW（參考 ID：C1919）發佈了用於生成本新聞簡報的原始內容，並對其中包含的信息負全部責任。© 版權 2026 - 公共技術公司（PUBT）

### Related Stocks

- [LBRX.US - LB Pharmaceuticals](https://longbridge.com/zh-HK/quote/LBRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued | LB Pharmaceuticals Inc. has raised $100 million through a private placement, issuing pre-funded warrants for 1,417,107 s | [Link](https://longbridge.com/zh-HK/news/274977918.md) |
| Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX) | Roth MKM analyst Boobalan Pachaiyappan has maintained a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price targe | [Link](https://longbridge.com/zh-HK/news/273861458.md) |
| LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression | LB Pharmaceuticals Inc. has launched a Phase 2 clinical trial, ILLUMINATE-1, to assess the efficacy and safety of LB-102 | [Link](https://longbridge.com/zh-HK/news/273704681.md) |
| LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM | LB Pharmaceuticals, Inc. (LBRX) has received a Buy rating and a price target of $31.00 from Roth MKM analyst Boobalan Pa | [Link](https://longbridge.com/zh-HK/news/272027134.md) |
| LB Pharmaceuticals Grants Chief Commercial Officer Stock Options Valued at $21.36 Per Share | LB Pharmaceuticals Inc. has granted Kaya Pai Panandiker, the new Chief Commercial Officer, an option to purchase 195,000 | [Link](https://longbridge.com/zh-HK/news/269290802.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。